The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Progression in Smoldering Myeloma Is Independently Determined by the Chromosomal Abnormalities del(17p), t(4;14), Gain 1q, Hyperdiploidy, and Tumor Load
Open accessAbstract
Purpose: The aim of this study was to analyze chromosomal aberrations in terms of frequency and impact on time to progression in patients with smoldering multiple myeloma (SMM) on the background of clinical prognostic factors. Patients and Methods: The chromosomal abnormalities 1q21, 5p15/5q35, 9q34, 13q14.3, 15q22, 17p13, t(11;14)(q13;q32), and t(4;14)(p16.3;q32) were assessed in CD138-purified myeloma cells by interphase fluorescent in situ hybridization (iFISH) alongside clinical parameters in a consecutive series of 248 patients with SMM. Results: The high-risk aberrations in active myeloma (ie, del(17p13), t(4;14), and +1q21) present in 6.1%, 8.9%, and 29.8% of patients significantly confer adverse prognosis in SMM with hazard ratios (HRs) of 2.90 (95% CI, 1.56 to 5.40), 2.28 (95% CI, 1.33 to 3.91), and 1.66 (95% CI, 1.08 to 2.54), respectively. Contrary to the conditions in active myeloma, hyperdiploidy, present in 43.3% of patients, is an adverse prognostic factor (HR, 1.67; 95% CI, 1.10 to 2.54). Percentage of malignant bone marrow plasma cells assessed by iFISH and combination of M-protein and plasma cell infiltration as surrogates of tumor load significantly confer adverse prognosis with HRs of 4.37 (95% CI, 2.79 to 6.85) and 4.27 (95% CI, 2.77 to 6.56), respectively. In multivariate analysis, high-risk aberrations, hyperdiploidy, and surrogates of tumor load are independently prognostic. Conclusion: The high-risk chromosomal aberrations del(17p13), t(4;14), and +1q21 are adverse prognostic factors in SMM just as they are in active myeloma, independent of tumor mass. Hyperdiploidy is the first example for an adverse prognostic factor in SMM of opposite predictiveness in active myeloma. Risk association of chromosomal aberrations is not only a priori treatment dependent (predictive) but is also an intrinsic property of myeloma cells (prognostic).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“patients with t(4;14) translocation, del(17p), and gain(1q) are at a higher risk of progression from MGUS or SMM to multiple myeloma.21–23”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [22]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,957
The International Myeloma Working Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04355.x · Cited by 2,367
Kyle, R. A., & Rajkumar, S. V. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041875 · Cited by 1,309
Landgren, O., Kyle, R. A., Pfeiffer, R. M., Katzmann, J. A., Caporaso, N. E., Hayes, R. B., Dispenzieri, A., Kumar, S., Clark, R. J., Baris, D., et al. (2009) · Blood · doi:10.1182/blood-2008-12-194241 · Cited by 1,127
Avet-Loiseau, H., Attal, M., Moreau, P., Charbonnel, C., Garban, F., Hulin, C., Leyvraz, S., Michallet, M., Yakoub-Agha, I., Garderet, L., et al. (2007) · Blood · doi:10.1182/blood-2006-08-040410 · Cited by 940
Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070389 · Cited by 921
The genetic architecture of multiple myeloma
Morgan, G. J., Walker, B. A., & Davies, F. E. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3257 · Cited by 913
Kyle, R. A., Durie, B. G. M., Rajkumar, S. V., Landgren, O., Bladé, J., Merlini, G., Kröger, N. M., Einsele, H., Vesole, D. H., Dimopoulos, M. A., et al. (2010) · Leukemia · doi:10.1038/leu.2010.60 · Cited by 886
Reporting Recommendations for Tumor Marker Prognostic Studies
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.0454 · Cited by 779
Cited by
Sorted by citations
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationMultiple myeloma: 2020 update on diagnosis, risk‐stratification and management
Rajkumar, S. V. (2020) · American Journal of Hematology · doi:10.1002/ajh.25791 · Cited by 830
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883
Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534
Multiple myeloma: 2016 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2016) · American Journal of Hematology · doi:10.1002/ajh.24402 · Cited by 466
Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
Rasche, L., Chavan, S. S., Stephens, O. W., Patel, P. H., Tytarenko, R., Ashby, C., Bauer, M., Stein, C., Deshpande, S., Wardell, C., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00296-y · Cited by 417
Multiple myeloma current treatment algorithms
Rajkumar, S. V., & Kumar, S. K. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00359-2 · Cited by 373
Seckinger, A., Delgado, J. A., Moser, S., Moreno, L., Neuber, B., Grab, A. L., Lipp, S., Merino, J., Prósper, F., Emde, M., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.002 · Cited by 313
Self-citationRisk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria
Lakshman, A., Rajkumar, S. V., Buadi, F. K., Binder, M., Gertz, M. A., Lacy, M. Q., Dispenzieri, A. A., Dingli, D., Fonder, A. L., Hayman, S. R., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0077-4 · Cited by 299
The multiple myelomas — current concepts in cytogenetic classification and therapy
Kumar, S. K., & Rajkumar, S. V. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0018-y · Cited by 302
circEPSTI1 as a Prognostic Marker and Mediator of Triple-Negative Breast Cancer Progression
Chen, B., Wei, W., Huang, X., Xie, X., Kong, Y., Dai, D., Yang, L., Wang, J., Tang, H., & Xie, X. (2018) · Theranostics · doi:10.7150/thno.24106 · Cited by 284
Rajkumar, S. V., Landgren, O., & Mateos, M. (2015) · Blood · doi:10.1182/blood-2014-09-568899 · Cited by 278
Evolutionary biology of high-risk multiple myeloma
Pawlyn, C., & Morgan, G. J. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.63 · Cited by 242
Interpretation of cytogenetic results in multiple myeloma for clinical practice
Rajan, A., & Rajkumar, S. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.92 · Cited by 219
Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2018) · American Journal of Hematology · doi:10.1002/ajh.25117 · Cited by 229
Multiple myeloma: 2014 Update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2014) · American Journal of Hematology · doi:10.1002/ajh.23810 · Cited by 215
Pathobiology and Diagnosis of Multiple Myeloma.
Brigle, K., & Rogers, B. (2017) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2017.05.012 · Cited by 187
McDonald, M. M., Reagan, M. R., Youlten, S. E., Mohanty, S. T., Seckinger, A., Terry, R. L., Pettitt, J. A., Simic, M. K., Cheng, T. L., Morse, A., et al. (2017) · Blood · doi:10.1182/blood-2017-03-773341 · Cited by 186
Self-citationMGUS to myeloma: a mysterious gammopathy of underexplored significance
Dhodapkar, M. V. (2016) · Blood · doi:10.1182/blood-2016-09-692954 · Cited by 179
Myeloma today: Disease definitions and treatment advances
Rajkumar, S. V. (2015) · American Journal of Hematology · doi:10.1002/ajh.24236 · Cited by 163
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma
Marchesini, M., Ogoti, Y., Fiorini, E., Samur, A. A., Nezi, L., D’Anca, M., Storti, P., Samur, M., Gañán‐Gómez, I., Fulciniti, M. T., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.05.011 · Cited by 160
Chromosome 1q21 abnormalities in multiple myeloma
Schmidt, T. M., Fonseca, R., & Usmani, S. Z. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00474-8 · Cited by 154
Immunosurveillance and therapy of multiple myeloma are CD226 dependent
Guillerey, C., de Andrade, L. F., Vučković, S., Miles, K. M., Ngiow, S. F., Yong, M. C. R., Teng, M. W. L., Colonna, M., Ritchie, D. S., Chesi, M., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77181 · Cited by 151
Zamagni, E., Nanni, C., Gay, F., Pezzi, A., Patriarca, F. F., Bellò, M., Rambaldi, I., Tacchetti, P., Hillengaß, J., Gamberi, B., et al. (2015) · Leukemia · doi:10.1038/leu.2015.291 · Cited by 144
Oben, B., Froyen, G., Maclachlan, K. H., Leongamornlert, D., Abascal, F., Zheng-Lin, B., Yellapantula, V., Derkach, A., Geerdens, E., Diamond, B. T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22140-0 · Cited by 129
Multiple myeloma with high-risk cytogenetics and its treatment approach
Hanamura, I. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03353-5 · Cited by 126
Merz, M., Hielscher, T., Wagner, B., Sauer, S., Shah, S., Raab, M., Jauch, A. T., Neben, K., Hose, D., Egerer, G., et al. (2014) · Leukemia · doi:10.1038/leu.2014.75 · Cited by 121
Self-citationGenetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications
Cardona‐Benavides, I. J., Ramón, C. D., & Gutierrez, N. C. (2021) · Cells · doi:10.3390/cells10020336 · Cited by 107
Mikulasova, A., Wardell, C. P., Murison, A., Boyle, E. M., Jackson, G. H., Smetana, J., Kufova, Z., Pour, L., Sandecka, V., Almasi, M., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.163766 · Cited by 101
Gain/Amplification of Chromosome Arm 1q21 in Multiple Myeloma
Hanamura, I. (2021) · Cancers · doi:10.3390/cancers13020256 · Cited by 93
López‐Corral, L., Corchete, L. A., Sarasquete, M. E., Mateos, M., García‐Sánz, R., Fermiñán, E., Lahuerta, J. J., Bladé, J., Oriol, A., Teruel, A. I., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.087809 · Cited by 90
Cowan, A., Ferrari, F., Freeman, S. S., Redd, R., El-Khoury, H., Perry, J., Patel, V., Kaur, P., Barr, H., Lee, D. J., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00386-6 · Cited by 86
Bochtler, T., Hegenbart, U., Kunz, C., Benner, A., Kimmich, C. R., Seckinger, A., Hose, D., Goldschmidt, H., Granzow, M., Dreger, P., et al. (2016) · Blood · doi:10.1182/blood-2015-10-676361 · Cited by 85
Self-citationPaiva, B., Mateos, M., Sánchez‐Abarca, L. I., Puig, N., Vídriales, M., López‐Corral, L., Corchete, L. A., Hernández, M., Bargay, J., de Arriba, F., et al. (2015) · Blood · doi:10.1182/blood-2015-10-662320 · Cited by 82
Smoldering multiple myeloma requiring treatment: time for a new definition?
Dispenzieri, A. A., Stewart, A. K., Chanan-Khan, A. A., Rajkumar, S. V., Kyle, R. A., Fonseca, R., Kapoor, P., Bergsagel, P. L., McCurdy, A. B. R., Gertz, M. A., et al. (2013) · Blood · doi:10.1182/blood-2013-08-520890 · Cited by 83
Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma
Ravi, P. K., Kumar, S. K., Larsen, J. T., Gonsalves, W. I., Buadi, F. K., Lacy, M. Q., Go, R. S., Dispenzieri, A. A., Kapoor, P., Lust, J. A., et al. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.65 · Cited by 77
Smoldering multiple myeloma current treatment algorithms
Rajkumar, S. V., Kumar, S. K., Lonial, S., & Mateos, M. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00719-0 · Cited by 76
Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
Kyle, R. A., Miguel, J. F. S., Mateos, M., & Rajkumar, S. V. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.06.005 · Cited by 73
Smoldering multiple myeloma risk factors for progression: a Danish population‐based cohort study
Sørrig, R., Klausen, T. W., Salomo, M., Vangsted, A. J., Østergaard, B., Gregersen, H., Frølund, U. C., Andersen, N. F., Helleberg, C., Andersen, K., et al. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12728 · Cited by 68
Ten‐year survivors in AL amyloidosis: characteristics and treatment pattern
Muchtar, E., Gertz, M. A., Lacy, M. Q., Go, R. S., Buadi, F. K., Dingli, D., Grogan, M. A., AbouEzzeddine, O. F., Hayman, S. R., Kapoor, P., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16096 · Cited by 66
Evolving diagnostic criteria for multiple myeloma
Rajkumar, S. V. (2015) · Hematology · doi:10.1182/asheducation-2015.1.272 · Cited by 66
MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology
Mateos, M., & Landgren, O. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40320-5_1 · Cited by 64
Qu, X., Li, H., Braziel, R. M., Passerini, V., Rimsza, L. M., Hsi, E. D., Leonard, J. P., Smith, S. M., Kridel, R., Press, O. W., et al. (2018) · Blood · doi:10.1182/blood-2018-07-865428 · Cited by 63
van de Donk, N. W. C. J., Mutis, T., Poddighe, P. J., Lokhorst, H. M., & Zweegman, S. (2016) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12504 · Cited by 62
Antigen-mediated regulation in monoclonal gammopathies and myeloma
Nair, S., Sng, J., Boddupalli, C. S., Seckinger, A., Chesi, M., Fulciniti, M., Zhang, L., Rauniyar, N., Lopez, M., Neparidze, N., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98259 · Cited by 60
Self-citationNatural history of multiple myeloma with de novo del(17p)
Lakshman, A., Painuly, U., Rajkumar, S. V., Ketterling, R. P., Kapoor, P., Greipp, P. T., Gertz, M. A., Buadi, F. K., Lacy, M. Q., Dingli, D., et al. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0191-y · Cited by 54
How I treat smoldering multiple myeloma
Ghobrial, I. M., & Landgren, O. (2014) · Blood · doi:10.1182/blood-2014-08-551549 · Cited by 52
Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma
Maura, F., Bolli, N., Rustad, E. H., Hultcrantz, M. L., Munshi, N. C., & Landgren, O. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.4659 · Cited by 50
Kyle, R. A., Larson, D. R., Therneau, T. M., Dispenzieri, A. A., Melton, L. J., Benson, J. T., Kumar, S. K., & Rajkumar, S. V. (2014) · The Lancet Haematology · doi:10.1016/s2352-3026(14)70001-8 · Cited by 52
Sawyer, J. R., Tian, E., Heuck, C. J., Epstein, J., Johann, D. J., Swanson, C. M., Lukacs, J. L., Johnson, M., Binz, R. L., Boast, A., et al. (2014) · Blood · doi:10.1182/blood-2013-12-546077 · Cited by 50
Wu, V., Moshier, E. L., Leng, S., Barlogie, B., Cho, H. J., Jagannath, S., Madduri, D., Mazumdar, M., Parekh, S. S., & Chari, A. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018016998 · Cited by 50
Musto, P., Engelhardt, M. M., Caers, J., Bolli, N., Kaiser, M., van de Donk, N. W. C. J., Terpos, E., Broijl, A., de Larrea, C. F., Gay, F., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.278519 · Cited by 51
Self-citationSeckinger, A., Hillengaß, J., Emde, M., Beck, S., Kimmich, C. R., Dittrich, T., Hundemer, M., Jauch, A. S., Hegenbart, U., Raab, M., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01676 · Cited by 47
Self-citationGame of Bones: How Myeloma Manipulates Its Microenvironment
Moser-Katz, T., Joseph, N. S., Dhodapkar, M. V., Lee, K. P., & Boise, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.625199 · Cited by 50
Classifying ultra-high risk smoldering myeloma
Waxman, A. J., Mick, R., Garfall, A. L., Cohen, A. D., Vogl, D. T., Stadtmauer, E. A., & Weiss, B. M. (2014) · Leukemia · doi:10.1038/leu.2014.313 · Cited by 42
Ludwig, H., Kainz, S., Schreder, M., Zojer, N., & Hinke, A. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101910 · Cited by 41
miRNAs in multiple myeloma - a survival relevant complex regulator of gene expression
Seckinger, A., Meißner, T., Moreaux, J., Beneš, V., Hillengaß, J., Castoldi, M., Zimmermann, J., Ho, A. D., Jauch, A., Goldschmidt, H., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5381 · Cited by 41
Self-citationUrbán, V. S., Ceglédi, A., & Mikala, G. (2022) · GeroScience · doi:10.1007/s11357-022-00698-x · Cited by 43
Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance
Lakshman, A., Paul, S., Rajkumar, S. V., Ketterling, R. P., Greipp, P. T., Dispenzieri, A. A., Gertz, M. A., Buadi, F. K., Lacy, M. Q., Dingli, D., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0030-3 · Cited by 37
Bochtler, T., Merz, M., Hielscher, T., Granzow, M., Hoffmann, K., Krämer, A., Raab, M. S., Hillengaß, J., Seckinger, A., Kimmich, C. R., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018023200 · Cited by 37
Self-citationShall we treat smoldering multiple myeloma in the near future?
Landgren, O. (2017) · Hematology · doi:10.1182/asheducation-2017.1.194 · Cited by 35
Merz, M., Moehler, T. M., Ritsch, J., Bäuerle, T., Zechmann, C. M., Wagner, B., Jauch, A. S., Hose, D., Kunz, C., Hielscher, T., et al. (2015) · European Radiology · doi:10.1007/s00330-015-3928-4 · Cited by 34
Self-citationBock, F. M., Lu, G. G., Srour, S. A., Gaballa, S. R., Lin, H. Y., Baladandayuthapani, V., Honhar, M., Stich, M., Shah, N. D., Bashir, Q., et al. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.09.003 · Cited by 34
The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective
Caers, J., de Larrea, C. F., Leleu, X. P., Heusschen, R., Zojer, N., Decaux, O., Kastritis, E., Minnema, M. C., Jurczyszyn, A. J., Beguin, Y. P., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0303 · Cited by 33
Genomewide profiling of copy‐number alteration in monoclonal gammopathy of undetermined significance
Mikulášová, A., Smetana, J., Wayhelová, M., Janyšková, H., Sandecká, V., Chyra, Z., Almáši, M., Jarkovský, J., Gregora, E., Kessler, P., et al. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12774 · Cited by 32
Aljama, M. A., Sidiqi, M. H., Lakshman, A., Dispenzieri, A. A., Jevremović, D., Gertz, M. A., Lacy, M. Q., Buadi, F. K., Dingli, D., Muchtar, E., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018024794 · Cited by 32
Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma
Merz, M., Hielscher, T., Schult, D., Mai, E. K., Raab, M. S., Hillengaß, J., Seckinger, A., Hose, D., Granzow, M., Jauch, A. S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0634-2 · Cited by 32
Self-citationBolomsky, A., Hose, D., Schreder, M., Seckinger, A., Lipp, S., Klein, B., Heintel, D., Ludwig, H., & Zojer, N. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0105-1 · Cited by 30
Self-citationLong Non-Coding RNAs in Multiple Myeloma
Nobili, L., Ronchetti, D., Agnelli, L., Taìana, E., Vinci, C., & Neri, A. (2018) · Genes · doi:10.3390/genes9020069 · Cited by 31
Maes, K., Smedt, E. D., Kassambara, A., Hose, D., Seckinger, A., Valckenborgh, E. V., Menu, E., Klein, B., Vanderkerken, K., Moreaux, J., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.3207 · Cited by 29
Self-citationRecommendations for Management of Secondary Antibody Deficiency in Multiple Myeloma
Giralt, S. A., Jolles, S. R. A., Kerre, T. C. C., Lazarus, H. M., Mustafa, S. S., Papanicolaou, G. A., Ria, R., Vinh, D. C., & Wingard, J. R. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.05.008 · Cited by 30
Zhou, X., Dierks, A., Kertels, O., Kircher, M., Schirbel, A., Samnick, S., Buck, A. K., Knorz, S., Böckle, D., Scheller, L., et al. (2020) · Cancers · doi:10.3390/cancers12082333 · Cited by 28
How I approach smoldering multiple myeloma
Vaxman, I., & Gertz, M. A. (2022) · Blood · doi:10.1182/blood.2021011670 · Cited by 28
Wennmann, M., Ming, W., Bauer, F., Chmelík, J., Klein, A., Uhlenbrock, C., Grözinger, M., Kahl, K.-C., Nonnenmacher, T., Debic, M., et al. (2023) · Investigative Radiology · doi:10.1097/rli.0000000000000986 · Cited by 28
Self-citationYang, C., Cimera, R., Aryeequaye, R., Jayakumaran, G., Sarungbam, J., Al‐Ahmadie, H. A., Gopalan, A., Sirintrapun, S. J., Fine, S. W., Tickoo, S. K., et al. (2020) · Modern Pathology · doi:10.1038/s41379-020-00667-9 · Cited by 31
Landgren, O. (2021) · Hematology · doi:10.1182/hematology.2021000303 · Cited by 30
Understanding DNA Damage Response and DNA Repair in Multiple Myeloma
Petrilla, C., Galloway, J., Kudalkar, R., Ismael, A., & Cottini, F. (2023) · Cancers · doi:10.3390/cancers15164155 · Cited by 24
Rajkumar, S. V., Bergsagel, P. L., & Kumar, S. K. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.12.001 · Cited by 26
Gao, L., Liu, Y., Li, Y., Feng, L., Wang, Z., Wen, L., Wang, F., Huang, X., Lu, J., & Lai, Y. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.01.013 · Cited by 24
Recent advances in understanding multiple myeloma
Dhakal, B., Girnius, S. K., & Hari, P. (2016) · F1000Research · doi:10.12688/f1000research.8777.1 · Cited by 25
Merz, M., Jauch, A. S., Hielscher, T., Mai, E. K., Seckinger, A., Hose, D., Bertsch, U., Neben, K., Raab, M. S., Salwender, H. J., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.168005 · Cited by 24
Self-citationVarga, C., & Comenzo, R. L. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0284-4 · Cited by 23
Li, C., Wendlandt, E. B., Darbro, B. W., Xu, H., Thomas, G. S., Tricot, G. J. K., Chen, F., Shaughnessy, J. D., & Zhan, F. (2021) · Cancers · doi:10.3390/cancers13030517 · Cited by 23
Wagner, V., Hose, D., Seckinger, A., Weiz, L., Meißner, T., Rème, T., Breitkreutz, I., Podar, K., Ho, A. D., Goldschmidt, H., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2529 · Cited by 22
Self-citationKazandjian, D. G., Mailankody, S., Korde, N., & Landgren, O. (2014) · PubMed · Cited by 21
The Role of Early Intervention in High-Risk Smoldering Myeloma
Joseph, N. S., Dhodapkar, M. V., & Lonial, S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_278915 · Cited by 22
Clemens, J., Seckinger, A., Hose, D., Theile, D., Longo, M., Haefeli, W. E., Burhenne, J., & Weiß, J. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2643-1 · Cited by 21
Self-citationDilemmas in Treating Smoldering Multiple Myeloma
Ahn, I. E., Mailankody, S., Korde, N., & Landgren, O. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.4351 · Cited by 20
Tomasson, M. H., Ali, M., Oliveira, V. D., Xiao, Q., Jethava, Y. S., Zhan, F., Fitzsimmons, A. M., & Bates, M. L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113621 · Cited by 21
Kapoor, P., & Rajkumar, S. V. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000350 · Cited by 19
C1orf35 contributes to tumorigenesis by activating c-MYC transcription in multiple myeloma
Luo, S., Xiong, D., Li, J., Li, G., Wang, Y., Zhang, J., Bu, X., Hu, W., & Hu, J. (2020) · Oncogene · doi:10.1038/s41388-020-1222-7 · Cited by 19
Wennmann, M., Goldschmidt, H., Mosebach, J., Hielscher, T., Bäuerle, T., Komljenovic, D., McCarthy, P. L., Merz, M., Schlemmer, H., Raab, M. S., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18232 · Cited by 18
Self-citationThe FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma
Giacomini, A., Taranto, S., Gazzaroli, G., Faletti, J., Capoferri, D., Marcheselli, R., Sciumé, M., Presta, M., Sacco, A., & Roccaro, A. M. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03217-2 · Cited by 19
State of the science in smoldering myeloma: Should we be treating in the clinic?
Hill, E., Dew, A., & Kazandjian, D. G. (2019) · Seminars in Oncology · doi:10.1053/j.seminoncol.2019.03.001 · Cited by 17
Zhao, A., Shen, K., Wang, J., Huo, L., Li, J., & Cao, X. (2019) · Cancer Management and Research · doi:10.2147/cmar.s205623 · Cited by 17
Fichtner, S., Hose, D., Engelhardt, M., Meißner, T., Neuber, B., Krasniqi, F., Raab, M. S., Schönland, S. O., Ho, A. D., Goldschmidt, H., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1618 · Cited by 16
Self-citationCytogenetic and FISH analysis of 93 multiple myeloma Moroccan patients
Hamdaoui, H., Benlarroubia, O., Boujmia, O. K. A., Mossafa, H., Ouldim, K., Belkhayat, A., Smyej, I., Benrahma, H., Dehbi, H., & Chegdani, F. (2020) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.1363 · Cited by 16
Yadav, U., Kumar, S. K., Baughn, L. B., Dispenzieri, A. A., Greipp, P. T., Ketterling, R. P., Jevremović, D., Buadi, F. K., Dingli, D., Lacy, M. Q., et al. (2023) · Blood · doi:10.1182/blood.2023021187 · Cited by 15
The consultant's guide to smoldering multiple myeloma
Þorsteinsdóttir, S., & Kristinsson, S. Y. (2022) · Hematology · doi:10.1182/hematology.2022000355 · Cited by 16
Smoldering Multiple Myeloma: Who and When to Treat
Mateos, M., & González‐Calle, V. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.06.022 · Cited by 15
Metadata
- Authors
- Neben, K., Jauch, A., Hielscher, T., Hillengass, J., Lehners, N., Seckinger, A., Granzow, M., Raab, M. S., Ho, A. D., Goldschmidt, H., & Hose, D.
- Affiliations
- German Cancer Research Center (DE)
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2013-12-01
- Volume
- 31
- Issue
- 34
- Pages
- 4325-4332
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2126894260
- Semantic Scholar
- 3454ef568a1d73e48a414842f0c56b0cc223ddf6
- Cited by
- 233
- References
- 32
- Citations by year
- 2026: 3 · 2025: 12 · 2024: 17 · 2023: 16 · 2022: 13 · 2021: 24 · 2020: 23 · 2019: 13 · 2018: 20 · 2017: 21 · 2016: 18 · 2015: 26 · 2014: 25 · 2013: 2
- FWCI
- 16.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (SFB TRR 79)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- smoldering multiple myeloma, progression to multiple myeloma, chromosomal abnormalities, 17p deletion, hyperdiploidy, tumor burden, prognostic factors, time to progression, M protein, plasma cell infiltration
- MeSH terms
- Chromosome Deletion, Chromosomes, Human, Pair 1, Chromosomes, Human, Pair 14, Chromosomes, Human, Pair 17, Chromosomes, Human, Pair 4, Humans, Multiple Myeloma, Phenotype, Ploidies, Risk Factors, Translocation, Genetic, Multivariate Analysis, Proportional Hazards Models, In Situ Hybridization, Fluorescence, Disease Progression, Genetic Predisposition to Disease, Tumor Burden
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
